ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Is a Good Night's Sleep at the Top of Your Wishlist?

Ashwagandha Helps Hormones - Aids Arthritis

Why You Should Be Eating More Porcini Mushrooms

A Breathalyzer for Disease?

How Bacopa Can Help Improve Your Cognitive Function

Magnesium Reduces Diabetes and Helps Keep You Young

Lavender Aromatherapy Can Ease Pre-Op Anxiety

Give Your Health a Much-Needed Boost With Geranium

The Role of Resveratrol in Achieving Optimal Health

Could Coconut Oil Help Reduce Antibiotics?

 
Print Page
Email Article

Clinical trial demonstrates safety, effectiveness of immunotherapy for AdV, BKV, and herpesviruses in transplant patients

  [ 1 vote ]   [ Discuss This Article ]
www.ProHealth.com • September 10, 2014


Clinical trial demonstrates safety, effectiveness of immunotherapy for AdV, BKV, and herpesviruses in transplant patients
Reprinted with the kind permission of the HHV-6 Foundation.

Baylor College of Medicine’s Center for Cell and Gene Therapy has demonstrated a way to quickly generate antiviral T cells for the treatment of opportunistic viral infections, and recently reported success in a small clinical trial. While bone marrow and stem cell transplantation have become increasingly common interventions for patients with cancer, blood disorders, and genetic diseases, these patients are still at risk for a variety of complications including opportunistic viral infections that have no specific treatments available.  Their novel therapy utilizes synthetic peptides to generate single T cell lines from stem cell donors, which consistently have specificity for up to five viruses (AdV, EBV, CMV, BKV, and HHV6) representing the most frequent causes of viral morbidity and mortality after HSCT.
 
This technique, called “adoptive transfer of virus-specific T cells (VSTs),” can be safe and effective, and offers many advantages over conventional antiviral treatment options because there is no toxicity and it can be used for patients infected with strains that are resistant to commonly used antivirals.  Unfortunately, the cells themselves have historically been complex to prepare and limited in their antiviral range.  However, after years of work that included development of an enhanced adoptive T cell immunotherapy specific to HHV-6B, as well as refining an immunotherapy technique for limiting the effects of EBV and a set of eleven viruses known to cause complications following hematopoietic stem cell transplantation (HSCT), this group’s novel approach now demonstrates the feasibility and clinical utility of rapidly generated single-culture VSTs .
 
The clinical trial targeted 12 immunogenic antigens from five viruses (EBV, AdV, CMV, BKV, and HHV-6).  Intractable CMV, EBV, and AdV infections have previously proved to be responsive to adoptive T cell transfer, but this is the first clinical trial that targeted both BKV and HHV-6, both of which are ubiquitous viruses that may cause severe and intractable disease in HSCT recipients. When administered to 11 recipients of allogeneic transplants in the current study, 8 of whom had up to four active infections with the targeted viruses, these VSTs proved safe in all subjects and produced an overall 94% virological and clinical response rate that was sustained long-term (15 complete and 2 partial responses).
 
With their new technology, the team can produce cells capable of destroying multiple infections at once in only 10 days. Previous methods took three months to manufacture and typically focused on only one virus. This therapeutic approach of isolating, treating and injecting patients with T cells may eventually prove to be the safest and most cost-effective alternative for immunocompromised patients with severe viral infections. The same immunotherapy technique has also been applied to advanced cervical cancer. Investigators reported in June that a single infusion of HPV-targeted T cell therapy induced a complete remission in two patients with advanced metastatic cervical cancer.
 
The authors also remark that there are many factors that cause transplant patients to be vulnerable to endogenous (latent) and exogenous (community acquired) viruses, including the cytotoxic drugs administered during the conditioning phase, the delay in immune recovery after the transplant, and the immunosuppressive drugs administered to prevent GVHD. There are currently no FDA approved rugs for the treatment of HHV-6, BK virus, adenovirus or EBV.
 
Journal Reference: Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, Leung K, Carrum G, Gee AP, Vera JF, Krance RA, Brenner MK, Rooney CM1, Heslop HE, Leen AM. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25;6(242):242ra83. doi: 10.1126/scitranslmed.3008825




Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Ultra EPA  - Fish Oil Vitamin D3 Extreme™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Breaking Through the Mental Fog Breaking Through the Mental Fog
Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial
Breakthrough Form of Magnesium Enhances Memory and Cognitive Function Breakthrough Form of Magnesium Enhances Memory and Cognitive Function
Can Glycine + Amino Acids Be the Secret to Deep, Rejuvenating Sleep? Can Glycine + Amino Acids Be the Secret to Deep, Rejuvenating Sleep?
Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map